Literature DB >> 10350027

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.

J G Ramaekers1, J W Louwerens, N D Muntjewerff, H Milius, A de Bie, P Rosenzweig, A Patat, J F O'Hanlon.   

Abstract

The primary objective of this study was to compare the objective and subjective effects of amisulpride with those of a classic antipsychotic, haloperidol, when both were given to healthy volunteers in representative therapeutic doses over 5 days. The secondary objective was to compare the effects of relatively low and high doses of amisulpride to confirm the suspected duality of its pharmacologic activity. Twenty-one subjects participated in the four-way, randomized, double-blind, crossover study with repeated daily doses of amisulpride 50 mg, amisulpride 400 mg, haloperidol 4 mg, and placebo. Subjects were institutionalized during treatment periods and were under 24-hour medical supervision. They underwent a series of psychomotor and cognitive tests 1 hour before and 3 and 6 hours after dosing on days 1 and 5. Their extrapyramidal disturbances and drug-related feelings were assessed at the end of each replication. Psychiatric interviews and ratings of depression, subjective well-being, and negative symptoms occurred on day 4. Amisulpride 50 mg had no significant effect on any parameter. Amisulpride 400 mg had several adverse effects on psychomotor and, although less severe, on cognitive performance on the fifth day only. Amisulpride 400 mg produced no significant extrapyramidal disturbances in the group as a whole, although it may have in some individual subjects. Also, it produced no signs of mental disturbances on clinical rating scales or during a structured psychiatric interview. Haloperidol ubiquitously impaired psychomotor and cognitive performance in a similar fashion after the first and the final doses. It produced extrapyramidal disturbances in nearly every subject, the most common being akathisia and the most severe, in the case of one individual, being acute dystonia. Unlike amisulpride, haloperidol produced a number of mental disturbances, the most noteworthy being negative symptoms. Amisulpride seems to be a well-tolerated drug. Its side effects should be much less troublesome to patients using the drug on a long-term basis than those of classic antipsychotics, like haloperidol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350027     DOI: 10.1097/00004714-199906000-00003

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  24 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.

Authors:  Anne Schmechtig; Jane Lees; Lois Grayson; Kevin J Craig; Rukiya Dadhiwala; Gerard R Dawson; J F William Deakin; Colin T Dourish; Ivan Koychev; Katrina McMullen; Ellen M Migo; Charlotte Perry; Lawrence Wilkinson; Robin Morris; Steve C R Williams; Ulrich Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2013-02-22       Impact factor: 4.530

3.  On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.

Authors:  Annemiek Vermeeren; Hong Sun; Eric F P M Vuurman; Stefan Jongen; Cees J Van Leeuwen; Anita C M Van Oers; John Palcza; Xiadong Li; Tine Laethem; Ingeborg Heirman; An Bautmans; Matthew D Troyer; Rebecca Wrishko; Jacqueline McCrea
Journal:  Sleep       Date:  2015-11-01       Impact factor: 5.849

4.  Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers.

Authors:  E R Samuels; R H Hou; R W Langley; E Szabadi; C M Bradshaw
Journal:  Psychopharmacology (Berl)       Date:  2006-06-27       Impact factor: 4.530

Review 5.  Spotlight on amisulpride in schizophrenia.

Authors:  Monique P Curran; Caroline M Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.

Authors:  Tim R M Leufkens; Annemiek Vermeeren; Beitske E Smink; Peter van Ruitenbeek; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

7.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

Review 8.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  M P Curran; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.

Authors:  Rosa Ayesa-Arriola; Jose Manuel Rodríguez-Sánchez; Rocío Pérez-Iglesias; Roberto Roiz-Santiáñez; Obdulia Martínez-García; Jose Sánchez-Moreno; Rafael Tabarés-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

10.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.